Form 4: Medpace Director Acquires Stock Options

Fred B. Davenport Jr., a Director and 10% Owner of Medpace Holdings, Inc., acquired 1,110 stock options with an exercise price of $415.27, vesting based on service.

Summary

• Fred B. Davenport Jr., a Director and 10% Owner of Medpace Holdings, Inc. (MEDP), acquired 1,110 stock options on May 15, 2026.
• The options have an exercise price of $415.27 per share and expire on May 15, 2033.
• They vest on the earlier of the day immediately preceding the first annual meeting of the Issuer following the grant date, or the first anniversary of the grant date, subject to continued service on the board of directors.
• Following this transaction, Mr. Davenport directly owns 1,110 derivative securities (stock options) and beneficially owns 3,498 shares of common stock directly and 2,000 shares indirectly through a trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the grant of stock options to a significant director and owner aligns their interests with long-term shareholder value, indicating confidence and commitment.

Positives

• The acquisition of stock options by a director and 10% owner indicates an alignment of interests with shareholders, as the options gain value if the stock price increases.
• The vesting schedule, contingent on continued service, incentivizes long-term commitment to the company's performance and strategic direction.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and aligns their future compensation with the company's long-term stock performance.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a standard practice in the pharmaceutical and contract research organization (CRO) industries, including companies like IQVIA Holdings Inc. (IQV) and Laboratory Corporation of America Holdings (LH), to align executive and director incentives with shareholder value creation. This particular grant to a 10% owner and director at Medpace Holdings (MEDP) reinforces commitment and provides a performance-linked incentive.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a common practice across publicly traded companies, including peers in the CRO sector such as Charles River Laboratories International, Inc. (CRL) and Syneos Health, Inc. (SYNH).
• The vesting schedule, tied to continued service and annual meetings, is typical for equity grants to non-employee directors, similar to practices observed at global benchmarks in the life sciences sector.
• An exercise price of $415.27, likely at or above the market price on the grant date, is standard for incentive stock options, ensuring the director benefits only if the company's stock appreciates.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The acquired stock options will vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of Medpace Holdings, Inc. following the grant date, and (ii) the first anniversary of the grant date.
• Vesting is subject to Fred B. Davenport Jr.'s continued service on the board of directors through the vesting date.
• The reporting person may exercise the vested options at any time between their vesting date and the expiration date of May 15, 2033.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director and 10% owner as part of their compensation. While it signals continued alignment of interests, it does not present new fundamental information that would significantly alter the investment thesis for Medpace Holdings, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Medpace Holdings, MEDP, Stock Options, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership, Equity Grant